Eli Lilly and Company announced today that the U.S. Food and Drug Administration (FDA) has approved Emgality® (galcanezumab-gnlm) injection (300 mg) for the treatment of episodic cluster headache in adults.
Eli Lilly and Company announced today that the U.S. Food and Drug Administration (FDA) has approved Emgality® (galcanezumab-gnlm) injection (300 mg) for the treatment of episodic cluster headache in adults.
© American Academy of Pain Medicine. All Rights Reserved.
American Academy of Pain (AAMP) is a nonprofit, 501(c)(3) tax-exempt organization.
1705 Edgewater Drive, #7778
Orlando, FL 32804
Phone: (800) 917-1619 Ext. 102
Fax: (407) 749-0714